Chemical Research in Toxicology · 1997 · 96 citations · 8 references
MedicineNeurosciencePharmacologyNeurochemistryNeurodegenerationNeuropharmacologyMonoamine NeurochemistryNeurodegenerative DiseasesNeuroprotectionNeuroprotective PharmacologyParkinson DiseaseParkinsonian DisordersMitochondrial Respiratory Chain InhibitionMitochondrial Respiratory Complex IMonoamine Oxidase InhibitionMonoamine Oxidase InhibitorsMonoamine Oxidase InvolvementMonoamine OxidasesNeuroprotective AgentsNitric Oxide
The neurodegenerative properties of the parkinsonian inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are thought to result from inhibition of complex I of the mitochondrial respiratory chain by the monoamine oxidase-B (MAO-B) generated 1-methyl-4-phenylpyridinium metabolite MPP+. Treatment with 7-nitroindazole (7-NI) protects rodents and baboons against MPTP's neurotoxicity, presumably as a consequence of its inhibition of neuronal nitric oxide synthase (nNOS). The results reported in the present communication, while not in conflict with the proposed role of nNOS, raise the possibility that the inhibition of MAO-B by 7-NI also may contribute to the observed neuroprotection.
8
Philip K. Moore, P Wallace, Z. Gaffen et al. · British Journal of Pharmacology · 1993 · 465 citations · Full text
M. Harfenist, Darryl J. Heuser, Charles T. Joyner et al. · Journal of Medicinal Chemistry · 1996 · 98 citations · Full text
Ulrike Thull, C Altomare, V. Carta et al. · Journal of Medicinal Chemistry · 1995 · 67 citations · Full text